On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ('BioRay') announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed C ...
Patient enrollment is expected to begin in the first half of 2025, subject to final protocol review by regulatory authorities ...
Scientists have uncovered a key mechanism in jellyfish embryos that provides new insights into how the body plan of these ...
Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...
Anillin (ANLN), a mitotic protein that regulates contractile ring assembly, has been reported as an oncoprotein. However, the function of ANLN in cancer cells, especially in the nucleus, has not been ...
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments ...
H.C. Wainwright initiated coverage on Surrozen Inc. (NASDAQ:SRZN) with a Buy rating and established a price target of $32.00. The clinical-stage biotechnology company, currently valued at ...
(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing ...
Matthew Caufield, an analyst from H.C. Wainwright, has initiated a new Buy rating on Surrozen (SRZN).Invest with Confidence: Follow TipRanks' ...
Announcing a new publication for Acta Materia Medica journal. The binding affinity of aptamers to targets has a crucial role in the pharmaceutical and biosensing effects. Despite diverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback